Studies showed that polydatin exerts therapeutic and protective effects through various mechanisms in the field of osteoporosis [209,210,211], such as activation of tafazzin (TAZ) [210] and regulation of osteoprotegerin, the receptor activator of NF-κB ligand (RANKL), and B-catenin [209]. The gene discussed is TAFAZZIN; the disease is osteoporosis.